PBYI Puma Biotechnology Inc
Price (delayed)
$3.34
Market cap
$165.7M
P/E Ratio
5.39
Dividend/share
N/A
EPS
$0.62
Enterprise value
$170.56M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
Highlights
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
The P/E is 51% lower than the last 4 quarters average of 10.9
Puma Biotechnology's quick ratio has decreased by 4.8% YoY
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
Key stats
What are the main financial stats of PBYI
Market
Valuations
Earnings
Shares outstanding
49.61M
Market cap
$165.7M
Enterprise value
$170.56M
Price to earnings (P/E)
5.39
Price to book (P/B)
1.78
Price to sales (P/S)
0.71
EV/EBIT
4.67
EV/EBITDA
3.55
EV/Sales
0.74
Revenue
$230.47M
Gross profit
$166.06M
Operating income
$30.97M
Net income
$30.28M
EBIT
$36.55M
EBITDA
$48.08M
Free cash flow
$38.86M
Per share
Balance sheet
Liquidity
EPS
$0.62
EPS diluted
$0.62
Free cash flow per share
$0.8
Book value per share
$1.88
Revenue per share
$4.74
TBVPS
$3.33
Total assets
$213.33M
Total liabilities
$121.21M
Debt
$74.08M
Equity
$92.13M
Working capital
$51.55M
Debt to equity
0.8
Current ratio
1.54
Quick ratio
1.38
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
20.9%
Gross margin
72.1%
Net margin
13.1%
Operating margin
13.4%
Return on assets
14.2%
Return on equity
46.1%
Return on invested capital
46.5%
Return on capital employed
31.2%
Return on sales
15.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PBYI stock price
How has the Puma Biotechnology stock price performed over time
Intraday
-5.11%
1 week
-7.61%
1 month
14.78%
1 year
-37.34%
YTD
9.51%
QTD
9.51%
Financial performance
How have Puma Biotechnology's revenue and profit performed over time
Revenue
$230.47M
Gross profit
$166.06M
Operating income
$30.97M
Net income
$30.28M
Gross margin
72.1%
Net margin
13.1%
Puma Biotechnology's net margin has increased by 42% YoY and by 38% QoQ
The net income has grown by 40% YoY and by 30% from the previous quarter
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
The operating income has contracted by 5% YoY and by 4.4% from the previous quarter
Growth
What is Puma Biotechnology's growth rate over time
Valuation
What is Puma Biotechnology stock price valuation
P/E
5.39
P/B
1.78
P/S
0.71
EV/EBIT
4.67
EV/EBITDA
3.55
EV/Sales
0.74
The P/E is 51% lower than the last 4 quarters average of 10.9
PBYI's EPS is up by 35% year-on-year and by 29% since the previous quarter
PBYI's P/B is 82% lower than its 5-year quarterly average of 9.7 and 39% lower than its last 4 quarters average of 2.9
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
PBYI's P/S is 29% below its 5-year quarterly average of 1.0 and 11% below its last 4 quarters average of 0.8
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
Efficiency
How efficient is Puma Biotechnology business performance
PBYI's ROIC is up by 49% YoY and by 4.7% QoQ
The ROA has increased by 37% YoY and by 33% QoQ
Puma Biotechnology's ROE has decreased by 21% YoY but it has increased by 11% from the previous quarter
PBYI's return on sales is up by 3.9% year-on-year and by 2.6% since the previous quarter
Dividends
What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PBYI.
Financial health
How did Puma Biotechnology financials performed over time
The total assets is 76% more than the total liabilities
The total liabilities has contracted by 32% YoY and by 19% from the previous quarter
The company's current ratio rose by 8% QoQ
Puma Biotechnology's debt is 20% lower than its equity
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
Puma Biotechnology's debt to equity has shrunk by 62% YoY and by 34% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.